The FINANCIAL — Pfizer Inc. and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.…
Read More »
The FINANCIAL — Pfizer Inc. and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from…
You might be interested in
The FINANCIAL — People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have…
Epidemiologist explains how to stay on guard against subvariants, noting role of protective measures in transition to new pandemic phase…
A new study measuring the impact of COVID-19 on the wellbeing and mental health of adolescents has found that the…
A federal judge struck down the government’s transportation mask mandate on Monday, making face coverings optional for passengers and employees.…